Mexico Approves Pfizer's Oral COVID-19 Treatment

Mexico's health regulator Cofepris has issued a favorable opinion for Pfizer's oral COVID-19 treatment, which could significantly reduce hospitalizations and deaths, offering hope in the country's pandemic fight.

author-image
Quadri Adejumo
Updated On
New Update
Mexico Approves Pfizer's Oral COVID-19 Treatment

Mexico Approves Pfizer's Oral COVID-19 Treatment

Mexico's health regulator, Cofepris, has issued a favorable opinion for Pfizer's oral antiviral treatment against SARS-CoV-2, setting the stage for the medicine to be marketed throughout the country. The treatment has demonstrated effectiveness in reducing the risk of hospitalization and death in high-risk COVID-19 patients.

Cofepris recognized the potential of Pfizer's oral treatment to contribute significantly to controlling the pandemic in Mexico. "This treatment has been shown to be effective in reducing the risk of hospitalization and death in high-risk COVID-19 patients," the regulator stated.

The Commission is expected to issue its final determination on the health registration of the drug in the coming weeks, which would allow for its commercialization in Mexico. The incorporation of Pfizer's oral treatment into the arsenal of tools available to combat COVID-19 is anticipated to have a positive impact on public health and the quality of life for thousands of Mexicans.

Why this matters: The approval of Pfizer's oral COVID-19 treatment in Mexico constitutes a significant step forward in the ongoing fight against the pandemic. With the potential to reduce hospitalizations and deaths, this treatment could help alleviate the burden on the country's healthcare system and save countless lives.

Cofepris' favorable opinion on Pfizer's oral antiviral treatment marks a hopeful milestone in Mexico's battle against COVID-19. As the country eagerly awaits the final determination from the Commission, the prospect of having an effective oral treatment readily available brings a renewed sense of optimism in the face of the ongoing global health crisis.

Key Takeaways

  • Mexico's health regulator Cofepris approves Pfizer's oral COVID-19 treatment.
  • Treatment shown to reduce hospitalization and death risk in high-risk patients.
  • Final health registration expected in coming weeks, enabling commercialization in Mexico.
  • Approval marks significant step in Mexico's fight against the pandemic.
  • Treatment could help alleviate burden on healthcare system and save lives.